Calithera Biosciences Company Profile (NASDAQ:CALA)

About Calithera Biosciences

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. Its lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, which is an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. Its lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. Hexokinase is an enzyme in the pathway that allows cancer cells to convert glucose to energy to fuel cancer cell growth.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: CALA
CUSIP:

Key Metrics:

Previous Close: $3.18
50 Day Moving Average: $3.16
200 Day Moving Average: $4.36
52-Week Range: $2.87 - $10.90
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -2.08
P/E Growth: -0.02
Market Cap: $58.47M
Outstanding Shares: 19,489,000
Beta: 2.44

Profitability:

Return on Equity: -53.52%
Return on Assets: -50.03%

Debt:

Current Ratio: 13.28%
Quick Ratio: 13.28%

Additional Links:

Companies Related to Calithera Biosciences:

Consensus Ratings for Calithera Biosciences (NASDAQ:CALA) (?)

Ratings Breakdown:	4 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$12.33 (311.11% upside)

Analysts' Ratings History for Calithera Biosciences (NASDAQ:CALA)

Show:

Date	Firm	Action	Rating	Price Target
6/8/2016	JMP Securities	Reiterated Rating	Buy
5/12/2016	Wells Fargo & Co.	Reiterated Rating	Buy
3/9/2016	JPMorgan Chase & Co.	Lower Price Target	Market Outperform	$20.00 -> $12.00
11/10/2015	Leerink Swann	Lower Price Target	Outperform	$19.00 -> $13.00
7/24/2015	Citigroup Inc.	Initiated Coverage	Buy	$11.00

(Data available from 9/24/2014 forward)

Earnings History for Calithera Biosciences (NASDAQ:CALA)

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
11/7/2016
8/9/2016	Q2	($0.52)	($0.55)	View	Listen
5/10/2016	Q1	($0.47)	($0.52)	View	Listen
3/15/2016	Q415	($0.56)	($0.44)	View	Listen
11/9/2015	Q3	($0.52)	($0.49)	View	Listen
8/10/2015	Q215	($0.45)	($0.44)	View	Listen
11/17/2014		($0.28)	($16.85)	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Calithera Biosciences (NASDAQ:CALA)

Current Year EPS Consensus Estimate: $-2.01 EPS
Next Year EPS Consensus Estimate: $-1.44 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q2 2016	1	($0.52)	($0.52)	($0.52)
Q3 2016	1	($0.56)	($0.56)	($0.56)
Q4 2016	1	($0.60)	($0.60)	($0.60)

(Data provided by Zacks Investment Research)

Dividend History for Calithera Biosciences (NASDAQ:CALA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Calithera Biosciences (NASDAQ:CALA)

Insider Ownership Percentage: 27.50%
Institutional Ownership Percentage: 48.26%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
11/16/2015	Curtis Hecht	VP	Sell	970	$6.58	$6,382.60
9/23/2015	Adage Capital Partners Gp Llc	Major Shareholder	Buy	106,968	$6.03	$645,017.04
9/4/2015	Adage Capital Partners Gp Llc	Major Shareholder	Buy	90,300	$5.93	$535,479.00
8/28/2015	Adage Capital Partners Gp Llc	Major Shareholder	Buy	172,126	$5.27	$907,104.02
10/15/2014	Adage Capital Partners Gp Llc	Major Shareholder	Buy	181,700	$6.96	$1,264,632.00
10/7/2014	Jean George	Director	Buy	300,000	$10.00	$3,000,000.00
10/7/2014	Morgenthaler Venture Partners	Major Shareholder	Buy	350,000	$10.00	$3,500,000.00
10/1/2014	Adage Capital Partners Gp Llc	Major Shareholder	Buy	800,000	$10.00	$8,000,000.00

(Data available from 1/1/2013 forward)

Latest Headlines for Calithera Biosciences (NASDAQ:CALA)

Date	Headline
	Are Analysts Bearish Calithera Biosciences Inc (NASDAQ:CALA) After Last Week? - Post News (NASDAQ:CALA) www.kentuckypostnews.com - September 24 at 8:17 AM
	Calithera Biosciences to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology ... - GlobeNewswire (press release) (NASDAQ:CALA) globenewswire.com - September 23 at 3:29 PM
	Calithera Biosciences to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology Roundtable (NASDAQ:CALA) finance.yahoo.com - September 22 at 9:42 AM
	Calithera Biosciences Incorporated (NASDAQ:CALA) Short Interest Decreased By 4.6% - Post News (NASDAQ:CALA) www.kentuckypostnews.com - September 17 at 8:52 AM
	Calithera Announces First Patient Dosed in a Phase I Study of CB-1158, the First-in-Class Inhibitor of the Immuno-Oncology Target Arginase (NASDAQ:CALA) finance.yahoo.com - September 15 at 12:20 PM
	Lightstone Ventures Adds Susan M. Molineaux as Scientific Advisor (NASDAQ:CALA) www.finsmes.com - September 14 at 8:16 AM
	Calithera Biosciences Announces CB-839 Clinical Data Selected for Oral Presentation at the 28th EORTC-NCI-AACR ... - GlobeNewswire (press release) (NASDAQ:CALA) globenewswire.com - September 8 at 6:46 AM
	Calithera Biosciences Announces CB-839 Clinical Data Selected for ... - EconoTimes (NASDAQ:CALA) www.econotimes.com - September 8 at 6:46 AM
	Stock Showing Gains in Today's Session: Calithera Biosciences, Inc. (NASDAQ:CALA) - Post News (NASDAQ:CALA) www.kentuckypostnews.com - September 7 at 9:05 PM
	Calithera Biosciences Announces CB-839 Clinical Data Selected for Oral Presentation at the 28th EORTC-NCI-AACR Symposium ... (NASDAQ:CALA) semiconductors.einnews.com - September 7 at 9:52 AM
	Calithera Biosciences Announces CB-839 Clinical Data Selected for Oral Presentation at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (NASDAQ:CALA) finance.yahoo.com - September 7 at 9:52 AM
	Calithera Biosciences to Present at Two Healthcare Conferences in September (NASDAQ:CALA) finance.yahoo.com - August 31 at 3:58 PM
	Calithera Biosciences, Inc. (NASDAQ:CALA) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:CALA) www.investornewswire.com - August 26 at 4:14 PM
	Stock Tracking Lower for the Quarter: Calithera Biosciences, Inc. (NASDAQ:CALA) - Post News (NASDAQ:CALA) www.kentuckypostnews.com - August 21 at 8:42 AM
	CALITHERA BIOSCIENCES, INC. Financials (NASDAQ:CALA) finance.yahoo.com - August 19 at 4:44 PM
	Market Movers: Tremor Video, Inc. (NYSE:TRMR), Calithera ... - KC Register (NASDAQ:CALA) www.kcregister.com - August 12 at 4:03 PM
	Calithera Biosciences' (CALA) CEO Susan Molineaux on Q2 2016 Results - Earnings Call Transcript (NASDAQ:CALA) seekingalpha.com - August 10 at 9:36 PM
	Calithera Biosciences Appoints Suzy Jones to Board of Directors (NASDAQ:CALA) finance.yahoo.com - August 10 at 9:35 PM
	CALITHERA BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:CALA) biz.yahoo.com - August 10 at 9:35 PM
	Edited Transcript of CALA earnings conference call or presentation 9-Aug-16 8:30pm GMT (NASDAQ:CALA) finance.yahoo.com - August 10 at 3:31 PM
	Calithera Biosciences' (CALA) CEO Susan Molineaux on Q2 2016 Results - Earnings Call Transcript - Seeking Alpha (NASDAQ:CALA) seekingalpha.com - August 9 at 10:39 PM
	Calithera reports 2Q loss (NASDAQ:CALA) sg.finance.yahoo.com - August 9 at 10:39 PM
	Calithera Biosciences Reports Second Quarter 2016 Financial Results and Recent Highlights (NASDAQ:CALA) finance.yahoo.com - August 9 at 5:12 PM
	CALITHERA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a (NASDAQ:CALA) biz.yahoo.com - August 9 at 5:12 PM
	Calithera Biosciences Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:CALA) biz.yahoo.com - August 9 at 5:12 PM
	Q2 2016 Calithera Biosciences Inc Earnings Release - Time Not Supplied (NASDAQ:CALA) biz.yahoo.com - August 9 at 12:57 PM
	Notable Runners: Ultrapar Participacoes SA (ADR)(NYSE:UGP), Calithera Biosciences Inc (NASDAQ:CALA) - NYSE Journal (press release) (NASDAQ:CALA) stockznews.com - August 8 at 4:05 PM
	Calithera Announces Enrollment of First Patient in CB-839 in Combination with Checkpoint Modulator (NASDAQ:CALA) finance.yahoo.com - August 4 at 12:41 PM
	Calithera Biosciences to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016 (NASDAQ:CALA) finance.yahoo.com - August 2 at 4:11 PM
	Calithera Biosciences, Inc. (NASDAQ:CALA) Updated Price Targets - FTSE News (NASDAQ:CALA) www.ftsenews.co.uk - July 30 at 1:47 PM
	Calithera Biosciences (CALA) Announces FDA Acceptance of IND Application for CB-1158 (NASDAQ:CALA) www.streetinsider.com - July 25 at 4:38 PM
	Calithera Biosciences (CALA) Announces FDA Acceptance of IND Application for CB-1158 - StreetInsider.com (NASDAQ:CALA) www.streetinsider.com - July 25 at 4:38 PM
	Calithera Biosciences Announces FDA Acceptance of Investigational New Drug Application for CB-1158, a Novel Arginase Inhibitor Targeting an Immune Metabolic Checkpoint (NASDAQ:CALA) finance.yahoo.com - July 25 at 8:00 AM
	Checking in on Stock Volatility for: Calithera Biosciences, Inc. (NASDAQ:CALA) - Engelwood Daily (NASDAQ:CALA) www.engelwooddaily.com - July 21 at 9:36 PM
	Biotech news that matter for investors: Calithera Biosciences, Inc. (NASDAQ:CALA), Relypsa, Inc. (NASDAQ:RLYP) - The Voice Registrar (NASDAQ:CALA) voiceregistrar.com - July 20 at 5:07 PM
	Heightened Volatility Spotted on Shares of: Calithera Biosciences, Inc. (NASDAQ:CALA) - Engelwood Daily (NASDAQ:CALA) www.engelwooddaily.com - July 19 at 4:07 PM
	Investor Watch: Volatility Recap on Shares of: Calithera Biosciences, Inc. (NASDAQ:CALA) - Engelwood Daily (NASDAQ:CALA) www.engelwooddaily.com - July 19 at 10:15 AM
	Calithera Biosciences Inc: A Big Bounce Could Be Brewing (NASDAQ:CALA) www.investing.com - July 18 at 9:03 AM
	Increased Volatility Noted on Shares of: Calithera Biosciences, Inc. (NASDAQ:CALA) - Engelwood Daily (NASDAQ:CALA) www.engelwooddaily.com - July 17 at 3:53 PM
	It Seems Calithera Biosciences Inc Will Go Down. Have Another Big Decline - Consumer Eagle (NASDAQ:CALA) www.consumereagle.com - July 16 at 4:00 PM
	Noting Unusual Volume on Shares of Calithera Biosciences, Inc. (NASDAQ:CALA) - Engelwood Daily (NASDAQ:CALA) www.engelwooddaily.com - July 16 at 4:00 PM
	Shares Experiencing a Downtrend: Calithera Biosciences, Inc. (NASDAQ:CALA) - TGP (NASDAQ:CALA) telanaganapress.com - July 16 at 4:00 PM
	Shares Moving Down on the Week: Calithera Biosciences, Inc. (NASDAQ:CALA) - Engelwood Daily (NASDAQ:CALA) www.engelwooddaily.com - July 16 at 4:00 PM
	Which way Calithera Biosciences, Inc. (NASDAQ:CALA) insiders are heading - Review Fortune (NASDAQ:CALA) reviewfortune.com - July 16 at 4:00 PM
	Calithera Biosciences Incorporated (NASDAQ:CALA) Short Interest Decreased By 3.29% - Consumer Eagle (NASDAQ:CALA) www.consumereagle.com - July 14 at 9:32 PM
	Eye on Stock Volatility for: Calithera Biosciences, Inc. (NASDAQ:CALA) - Engelwood Daily (NASDAQ:CALA) www.engelwooddaily.com - July 14 at 9:32 PM
	ImmunoGen, CVR Top Thursday’s 52-Week Low Club (NASDAQ:CALA) 247wallst.com - July 14 at 4:04 PM
	Calithera Biosciences, Inc. (CALA) Hits a New 52-Week Low - Finance Daily (NASDAQ:CALA) www.fidaily.com - July 13 at 4:06 PM
	Calithera Biosciences (NASDAQ:CALA) First Quarter Institutional Investor Sentiment Steady - Consumer Eagle (NASDAQ:CALA) www.consumereagle.com - July 13 at 4:06 PM
	Strong Sell Calls For Calithera Biosciences, Inc. (NASDAQ:CALA) At 0 - Investor Newswire (NASDAQ:CALA) www.investornewswire.com - July 13 at 4:06 PM